Results 221 to 230 of about 11,994 (242)
Some of the next articles are maybe not open access.
2009
Fungal infections are known to cause not only superficial diseases, such as athlete's foot and onychomycoses, but also those that become disseminated and life-threatening; serious invasive fungal infections caused by Candida spp., Cryptococcus neoformans, Aspergillus spp., Pneumocystis carinii and H...
Akihiko Fujie +2 more
openaire +2 more sources
Fungal infections are known to cause not only superficial diseases, such as athlete's foot and onychomycoses, but also those that become disseminated and life-threatening; serious invasive fungal infections caused by Candida spp., Cryptococcus neoformans, Aspergillus spp., Pneumocystis carinii and H...
Akihiko Fujie +2 more
openaire +2 more sources
Nebulizer Delivery of Micafungin Aerosols
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2011Study Objectives. To determine the optimal nebulization system for aerosolizing micafungin and to further assess the physiochemical properties of aerosolized micafungin.Design. In vitro experiment.Setting. University research center.Nebulizers. Pari LC Star, Hudson Updraft, Small Volume Nebulizer, and Aeroclipse II.Measurements and Main Results.
Thomas P. Winkler +4 more
openaire +3 more sources
Mycoses, 2012
SummaryInvasive candidiasis and mucosal candidiasis are among the most important health care associated infections; in its invasive form, candidiasis is associated with substantial morbidity and mortality. Among the currently available antifungal agents, the echinocandins are the among the most potent agents against Candida species.
openaire +2 more sources
SummaryInvasive candidiasis and mucosal candidiasis are among the most important health care associated infections; in its invasive form, candidiasis is associated with substantial morbidity and mortality. Among the currently available antifungal agents, the echinocandins are the among the most potent agents against Candida species.
openaire +2 more sources
Breakthrough Candidemia In Children On Micafungin
Pediatric Infectious Disease Journal, 2018We identified 8 pediatric patients on micafungin (MCFG; ≥3 doses) at our institution who had breakthrough candidemia (BC). The causative strains of the BC were Candida parapsilosis in 7 patients. The minimum inhibitory concentration of MCFG was ≤1 µg/mL (susceptible) in all 8 isolates.
Takanori Funaki, Isao Miyairi
openaire +2 more sources
Expert Review of Anti-infective Therapy, 2011
Invasive fungal infections (IFIs) are one of the major reasons for morbidity and mortality in immunocompromised children. The majority of IFIs are caused by Candida and Aspergillus species. Early diagnosis and prompt initiation of appropriate antifungal therapy is essential for favorable outcome.
openaire +2 more sources
Invasive fungal infections (IFIs) are one of the major reasons for morbidity and mortality in immunocompromised children. The majority of IFIs are caused by Candida and Aspergillus species. Early diagnosis and prompt initiation of appropriate antifungal therapy is essential for favorable outcome.
openaire +2 more sources
Drugs of Today, 2002
FK-463 (micafungin) represents the latest development candidate in a novel chemical class of echinocandin lipopeptide antifungal compounds. This agent has potent in vitro and experimental in vivo activity against a variety of pathogenic Candida species (yeasts) and Aspergillus fumigatus (filamentous fungus). This compound has favorable pharmacokinetics
openaire +3 more sources
FK-463 (micafungin) represents the latest development candidate in a novel chemical class of echinocandin lipopeptide antifungal compounds. This agent has potent in vitro and experimental in vivo activity against a variety of pathogenic Candida species (yeasts) and Aspergillus fumigatus (filamentous fungus). This compound has favorable pharmacokinetics
openaire +3 more sources
Micafungin: A New Echinocandin Antifungal
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007The echinocandins represent the newest class of antifungals to combat infections caused by Candida sp. Micafungin is an echinocandin recently approved by the United States Food and Drug Administration. It is indicated in adults for esophageal candidiasis and prophylaxis against candidal infections in hematopoietic stem cell transplant recipients ...
Jomy M. Joseph +2 more
openaire +3 more sources
Biological Properties and Analytical Methods for Micafungin: A Critical Review
Critical reviews in analytical chemistry, 2020Micafungin is characterized as one of the most active available drugs for candidemia treatment; however, their use is also associated in prophylaxis protocols in cases of invasive fungal infections.
G. Marena +3 more
semanticscholar +1 more source
Micafungin and a case of polymorphic ventricular tachycardia
Journal of Clinical Pharmacy and Therapeutics, 2016Although echinocandins are relatively safe antifungal drugs, cardiovascular toxicity is an emerging adverse event. This report reviews those side effects and describes a case of polymorphic ventricular tachycardia suggestive of torsades de pointes with micafungin.The patient was on micafungin for oesophageal candidiasis due to drug-drug interactions ...
P. J. Shah +3 more
openaire +3 more sources
Journal of the American Medical Association (JAMA), 2016
Importance Although frequently used in treating intensive care unit (ICU) patients with sepsis, empirical antifungal therapy, initiated for suspected fungal infection, has not been shown to improve outcome.
J. Timsit +25 more
semanticscholar +1 more source
Importance Although frequently used in treating intensive care unit (ICU) patients with sepsis, empirical antifungal therapy, initiated for suspected fungal infection, has not been shown to improve outcome.
J. Timsit +25 more
semanticscholar +1 more source